QRG Capital Management Inc. Has $1.99 Million Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

QRG Capital Management Inc. cut its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 12.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 129,430 shares of the company's stock after selling 18,708 shares during the quarter. QRG Capital Management Inc.'s holdings in Teva Pharmaceutical Industries were worth $1,989,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. lifted its position in shares of Teva Pharmaceutical Industries by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 92,471 shares of the company's stock valued at $2,038,000 after acquiring an additional 2,752 shares in the last quarter. Sanctuary Advisors LLC lifted its position in Teva Pharmaceutical Industries by 132.4% in the fourth quarter. Sanctuary Advisors LLC now owns 81,643 shares of the company's stock worth $1,799,000 after buying an additional 46,514 shares during the last quarter. CIBC Asset Management Inc boosted its stake in shares of Teva Pharmaceutical Industries by 14.1% during the 4th quarter. CIBC Asset Management Inc now owns 120,328 shares of the company's stock worth $2,652,000 after purchasing an additional 14,865 shares during the period. D.A. Davidson & CO. raised its holdings in shares of Teva Pharmaceutical Industries by 2.8% in the fourth quarter. D.A. Davidson & CO. now owns 88,919 shares of the company's stock worth $1,960,000 after buying an additional 2,408 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $104,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.55% of the stock is currently owned by company insiders.

Analyst Ratings Changes

TEVA has been the subject of a number of recent research reports. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Finally, Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $24.44.

Teva Pharmaceutical Industries Stock Up 0.1%

NYSE:TEVA traded up $0.01 during trading hours on Monday, hitting $16.96. The company's stock had a trading volume of 10,136,615 shares, compared to its average volume of 10,256,693. The stock has a fifty day moving average of $16.46 and a 200-day moving average of $17.41. The stock has a market capitalization of $19.45 billion, a P/E ratio of -14.75, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm's quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.